On December 7, 2020 Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, reported that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number ZL201380071109.8 (Press release, Enlivex Therapeutics, DEC 7, 2020, View Source [SID1234572313]). The patent covers AllocetraTM, the Company’s immunotherapy product candidate. The new patent provides added intellectual property protection in China, including methods, uses and pharmaceutical compositions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AllocetraTM has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as "unmet medical needs", including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumors’ microenvironment.